Today we welcome Karyopharm Therapeutics (Nasdaq:KPTI) into the Clinipace family of strategic pharma and biotech clients. Based in Natick, Massachusetts, Karyopharm is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.
As part of a long-term strategic partnership, we will manage several clinical programs and study starts for Karyopharm in 2014, including oncology, wound healing, and other diseases.
Sharon Shacham, Ph.D., MBA, Founder, President and Chief Scientific Officer, Karyopharm Therapeutics, commented:
“It is our mission to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture. By partnering with a like-minded technology-driven company like Clinipace, we believe we can help accelerate our first-in-class small molecule modulators into effective targeted therapeutics for life threatening conditions.”